SYP-2590
/ Samyang Group
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 28, 2026
Samyang Biopharmaceuticals will foster the next-generation drug delivery (DDS) platform "SENS" as a future growth engine.
(Maeil Business Newpaper)
- "'We are developing with the aim of submitting a clinical trial plan (IND) for idiopathic pulmonary fibrosis (IPF) treatment at the end of next year.'"
New trial • Idiopathic Pulmonary Fibrosis
1 to 1
Of
1
Go to page
1